Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Gains from Sales and Divestitures (2016 - 2025)

Historic Gains from Sales and Divestitures for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $372218.0.

  • Amphastar Pharmaceuticals' Gains from Sales and Divestitures fell 423.24% to $372218.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $372218.0, marking a year-over-year decrease of 423.24%. This contributed to the annual value of $388816.0 for FY2024, which is 1172.98% down from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' Gains from Sales and Divestitures stood at $372218.0, which was down 423.24% from $367827.0 recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Gains from Sales and Divestitures peaked at $493718.0 during Q4 2021, and registered a low of $338280.0 during Q1 2025.
  • In the last 5 years, Amphastar Pharmaceuticals' Gains from Sales and Divestitures had a median value of $417007.0 in 2022 and averaged $422272.5.
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Gains from Sales and Divestitures crashed by 2169.92% in 2021 and then increased by 0.82% in 2022.
  • Quarter analysis of 5 years shows Amphastar Pharmaceuticals' Gains from Sales and Divestitures stood at $493718.0 in 2021, then fell by 3.17% to $478068.0 in 2022, then fell by 7.86% to $440484.0 in 2023, then dropped by 11.73% to $388816.0 in 2024, then fell by 4.27% to $372218.0 in 2025.
  • Its Gains from Sales and Divestitures was $372218.0 in Q3 2025, compared to $367827.0 in Q2 2025 and $338280.0 in Q1 2025.